GlobeNewswire

Kevin Gaskell, Acclaimed CEO, to Deliver Keynote at ConnectWise IT Nation Europe

Dela

Conference Registration Deadline Quickly Approaching for Companies that Sell, Service and Support Technology

 

LONDON, March 26, 2018 (GLOBE NEWSWIRE) -- Now is the time for technology professionals to beat the registration deadline for IT Nation Europe, an annual ConnectWise conference that provides three days of education, networking and collaboration for technology team members. This year's event takes place 18-20 April.

Kevin Gaskell, serial entrepreneur and former CEO of multiple companies, including Porsche, BMW and Lamborghini, will be the guest keynote speaker. He has founded companies large and small - the smallest has four employees, the largest over 600 - and is the author of Inspired Leadership: How You Can Achieve Extraordinary Results in Business.

Gaskell said his IT Nation Europe keynote will draw on his 25 years of experience building and managing companies, and will provide audience members practical advice, tools and processes that they can begin to use the following day to inspire their teams to build world-class businesses.

"The goal is not to build big companies but to build great companies," he said.

ConnectWise CEO Arnie Bellini, who will kick off the conference with the opening keynote on 19 April, said this year's event will have something for all technology teams, no matter the size of their businesses.

"Our inaugural IT Nation Europe conference last year received such amazing feedback from the 300 plus attendees that we've upped the ante this year to bring our partners, prospects and vendors an even more robust agenda," Bellini said. "I am confident that no matter your role in the ecosystem, you'll find these three days of collaboration, networking and education well worth your time as they help you move closer to achieving your business goals."

Included among the many speakers scheduled for IT Nation Europe speakers are Craig Fulton, Chief Product Officer for ConnectWise; Brad Schow, Vice President for HTG Peer Groups; John Whitty, CEO, Solar Communications; and Nigel Houlden, Head of the Technology Policy, Information Commissioner's Office (ICO), who will discuss the GDPR, what type of data falls under the scope, and technology solution provider responsibilities.

In addition to the two keynotes and the much-anticipated GDPR enforcement discussion with ICO's Houlden, conference attendees will have access to:    

  • More than 10 hours of dedicated ConnectWise product training;
  • 50 breakout sessions with speakers representing top MSPs, industry thought leaders and ConnectWise product experts;
  • Multiple networking opportunities with other IT solution providers, ConnectWise colleagues and industry vendors;
  • And an inaugural gala during which ConnectWise will announce winners for Partner of the Year and Ecosystem Vendor of the Year.

Dan Scott, Quality and Implementation Manager, Complete I.T. Ltd, attended last year's IT Nation Europe conference and said he considers it the "must see" event of the year. "The value I gained from a unique combination of valuable educational content, sponsors and, most importantly, networking with a community of industry peers who all contribute, share and inspire in equal measure was immeasurable," he said.

This year's event will be held at the Hilton London Metropole. To learn more about IT Nation Europe and register, visit the ConnectWise IT Nation Europe website.  

Follow ConnectWise  
LinkedIn
ConnectWise Blog
Twitter
Facebook
YouTube

About ConnectWise
ConnectWise transforms how technology solution providers successfully build, manage and grow their businesses. Our award-winning set of software solutions provides a fully integrated, seamless experience to companies in more than 50 countries, giving them the ability to increase their productivity, efficiency and profitability. When combined with our relentless commitment to innovation, powerful network of ideas and experts, unparalleled passion for our users, and more than 35 years of experience, ConnectWise software solutions deliver the support companies want at each step of their business journey. For more information, visit www.ConnectWise.com.

Press Contacts
Elizabeth Bassler
EBassler@ConnectWise.com

Diane Rose for ConnectWise
diane@dkrcomms.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/75f7aada-20c1-4ee4-9b94-58ea8a896e0b




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ConnectWise via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum